PDA exam 3 gulsiven drugs

sulfonylurea: tolbutamide

• 1st gen

• shortest DOA bc of methyl

sulfonylurea: chlorpropamide

• 1st gen

• long half life

sulfonylurea: tolazamide

• 1st gen

• middle DOA

sulfonylurea: glimepride

• 2nd gen

• bulk increases cardiovascular effects

sulfonylurea: glipizide

• 2nd gen

• bulk increases cardiovascular effects

sulfonylurea: glyburide

• 2nd gen

• bulk increases cardiovascular effects

metformin

• delay progression of T2DM

• insulin sensitivity

• uptake

  • OCT1 gene deltion

  • can be variable

thiazolidinediones

• insulin sensitizers

• Regulate the transcription of genes involved in adipogenesis and lipid metabolism

ciglitazone

rosiglitazone

pioglitazone- hydroxy on the elthyl for metabolism

meglitinides

stimulate beta cells to secrete insulin

repaglinide

nateglinide

DPP-4 inhibitors

• prevent degradation of GLP-1 and stimulate insulin production

sitagliptin

saxgliptin

linagliptin

alogliptin

SGLT2 inhibitors

• reabsorption of filtered glucose in the kidney

• low risk of hypoglycemia

sglt2 inhibitors

semaglutide

• oral

  • allows transient permeabilization and concentration-driven uptake

orforglipron

• no injections or metabolic instability